Monday, March 15, 2010

Abbott files Hatch-Waxman case against Impax over Trilipix

Trilipix is a drug designed to raise "good" cholesterol while lowering "bad" cholesterol and triglycerides. Impax did a paragraph IV Hatch-Waxman filing and Abbott filed an infringement suit against Impax.

As to stock prices, Impax stock rose 38 cents, or 2.3 percent, to $16.87. Shares of Chicago-based Abbott lost 15 cents to $54.37.


Post a Comment

<< Home